These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15473023)

  • 1. Cetuximab in colon cancer.
    Martin MJ
    N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473023
    [No Abstract]   [Full Text] [Related]  

  • 2. The price tag on progress--chemotherapy for colorectal cancer.
    Schrag D
    N Engl J Med; 2004 Jul; 351(4):317-9. PubMed ID: 15269308
    [No Abstract]   [Full Text] [Related]  

  • 3. Cetuximab in colon cancer.
    Costa AF; Sander GB; Picon PD
    N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473024
    [No Abstract]   [Full Text] [Related]  

  • 4. New treatment options for colorectal cancer.
    Erlichman C; Sargent DJ
    N Engl J Med; 2004 Jul; 351(4):391-2. PubMed ID: 15269321
    [No Abstract]   [Full Text] [Related]  

  • 5. Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis.
    Norum J
    J Chemother; 2006 Oct; 18(5):532-7. PubMed ID: 17127231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
    Goldstein DA; El-Rayes BF
    Oncologist; 2015 Sep; 20(9):981-2. PubMed ID: 26265225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making.
    Franken MD; Koopman M; van Oijen MG
    Am J Clin Oncol; 2016 Apr; 39(2):214. PubMed ID: 26999056
    [No Abstract]   [Full Text] [Related]  

  • 8. NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy.
    Rinaldi F; George E; Adler AI
    Lancet Oncol; 2012 Mar; 13(3):233-4. PubMed ID: 22489288
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan--a Belgian analysis.
    Annemans L; Van Cutsem E; Humblet Y; Van Laethem JL; Bleiberg H
    Acta Clin Belg; 2007; 62(6):419-25. PubMed ID: 18351186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New combinations in metastatic colorectal cancer: what are our expectations?
    Hurwitz H
    Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
    [No Abstract]   [Full Text] [Related]  

  • 11. [Utilizing synergism].
    Krankenpfl J; 2005; 43(4-6):145. PubMed ID: 16171088
    [No Abstract]   [Full Text] [Related]  

  • 12. New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor.
    Vincenzi B; Santini D; Tonini G
    J Clin Oncol; 2006 Apr; 24(12):1957; author reply 1957-8. PubMed ID: 16622275
    [No Abstract]   [Full Text] [Related]  

  • 13. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
    Saltz LB
    Nat Clin Pract Oncol; 2005 Jan; 2(1):20-1. PubMed ID: 16264850
    [No Abstract]   [Full Text] [Related]  

  • 14. ERBITUX as a single agent and in combination in colorectal carcinoma.
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):242. PubMed ID: 12113039
    [No Abstract]   [Full Text] [Related]  

  • 15. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
    Li J
    Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):796-7. PubMed ID: 17366800
    [No Abstract]   [Full Text] [Related]  

  • 17. [Progress of chemotherapy in colorectal cancer].
    Komatsu Y
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1771-6. PubMed ID: 18064761
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Our experience of the treatment with cetuximab for unresectable advanced colorectal cancer].
    Yokomizo H; Yoshimatsu K; Osawa G; Matsumoto A; Otani T; Yano Y; Itagaki H; Fujimoto T; Umehara A; Ogawa K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2249-51. PubMed ID: 21224537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab in colorectal cancer.
    Sharieff W
    N Engl J Med; 2004 Oct; 351(16):1690-1; author reply 1690-1. PubMed ID: 15490497
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.